Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Papilloguard
- Development stage
- Unknown
- Lead developer
- Noyan Pajouhan biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Papilloguard is an Iranian-developed recombinant human papillomavirus (HPV) vaccine developed by Noyan Pajouhan Biopharma and its spin-off Nivad Pharmed Salamat. The primary formulation of Papilloguard is a bivalent vaccine targeting the major capsid L1 proteins of high-risk HPV types 16 and 18, which are responsible for the majority of cervical cancers. It is formulated as virus-like particles (VLPs) expressed in a recombinant system and adjuvanted with a synthetic monophosphoryl lipid A (synMPL) combined with aluminum hydroxide (an adjuvant system similar to AS04). Clinical trials have demonstrated its noninferiority in immunogenicity and safety compared to the reference bivalent vaccine, Cervarix. Additionally, a quadrivalent formulation, Papilloguard 4, which targets HPV types 6, 11, 16, and 18, has been developed and evaluated in Phase III trials against Gardasil for the prevention of genital warts and HPV-related cancers.
- Brand names
- PapilloguardPapilloguard 2Papilloguard2Papilloguard-2Papilloguard 4Papilloguard4Papilloguard-4
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Papilloguard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Papilloguard.